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Although many genetic association studies have been carried
out, it remains unclear which genes contribute to depression.
This may be due to heterogeneity of the DSM-IV category of
depression. Speciﬁc symptom-dimensions provide a more
homogenous phenotype. Furthermore, as effects of individual
genes are small, analysis of genetic data at the pathway-level
provides more power to detect associations and yield valuable
biological insight. In 1,398 individuals with a Major Depressive
Disorder, the symptom dimensions of the tripartite model of
anxiety and depression, General Distress, Anhedonic Depres-
sion, and Anxious Arousal, were measured with the Mood and
Anxiety Symptoms Questionnaire (30-item Dutch adaptation;
MASQ-D30). Association of these symptom dimensions with
candidate gene sets and gene sets from two public pathway
databases was tested using the Global test. One pathway was
associated with General Distress, and concerned molecules
expressed in the endoplasmatic reticulum lumen. Seven path-
ways were associated with Anhedonic Depression. Important
themes were neurodevelopment, neurodegeneration, and cytos-
keleton. Furthermore, three gene sets associated with Anxious
Arousal regarded development,morphology, and genetic recom-
bination. The individual pathways explained up to 1.7% of the
variance. These data demonstratemechanisms that inﬂuence the
speciﬁc dimensions. Moreover, they show the value of using
dimensional phenotypes on one hand and gene sets on the other
hand.  2012 Wiley Periodicals, Inc.
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INTRODUCTION
Major depressive disorder (MDD) is highly prevalent, with a
lifetime prevalence of 15% [Weissman et al., 1993]. Patients
with MDD vary widely with respect to their symptom proﬁles. If
this is not taken into account, symptom-speciﬁc risk factors
will remain undetected. Further, extensive comorbidity between
depressive and anxiety disorders exists, suggesting that part of their
pathogenesis is shared [Mineka et al., 1998; Vollebergh et al.,
2001; Kendler et al., 2003]. These problems can be overcome by
addressing the etiology of underlying, homogeneous symptom
dimensions. The tripartite model of anxiety and depression is a
well-validated dimensional model [Clark and Watson, 1991].
The dimension of General Distress (i.e., negative affect) contains
symptoms common to both depression and anxiety, including
irritability, hopelessness and guilt. The dimension of Anhedonic
Depression (i.e., lack of positive affect) refers to lack of energy and
enthusiasm, and is most speciﬁc to depression. The dimension of
Anxious Arousal (i.e., somatic arousal) is most speciﬁc to anxiety,
and consists of symptoms of somatic tension and hyperarousal.
Additional supporting information may be found in the online version of
this article.
Grant sponsor: Netherlands Organisation for Health Research and
Development (ZonMw); Grant number: 10-000-1002.
All authors report no conﬂicts of interest.
*Correspondence to:
Tineke van Veen, Department of Psychiatry, Leiden University Medical
Centre, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
E-mail: t.van_veen@lumc.nl
Article ﬁrst published online in Wiley Online Library
(wileyonlinelibrary.com): 9 May 2012
DOI 10.1002/ajmg.b.32058
How to Cite this Article:
van Veen T, Goeman JJ, Monajemi R,
Wardenaar KJ, Hartman CA, Snieder H,
Nolte IM, Penninx BWJH, Zitman FG. 2012.
Different Gene Sets Contribute to Different
Symptom Dimensions of Depression and
Anxiety.
Am J Med Genet Part B 159B:519–528.
 2012 Wiley Periodicals, Inc. 519
Neuropsychiatric Genetics
The coverage of these dimensions is quite speciﬁc and likely
inﬂuenced by fewer genes than the broad phenotype of MDD.
Furthermore, the dimensions are continuous and therefore provide
more statistical power to detect small genetic effects [MacCallum
et al., 2002]. A recent simulation study indeed demonstrated that
much power is gained when the multidimensionality of the
phenotype is taken into account, such that genetic effects speciﬁc
to certain phenotype dimensions can be detected [van der Sluis
et al., 2010]. Thus, it is not very surprising that genome-wide
association studies (GWAS) for MDD yielded no signiﬁcant asso-
ciations [Sullivan et al., 2009; Muglia et al., 2010; Wray et al., 2010;
Shi et al., 2011; Shyn et al., 2011]. Further, studies of candidate genes
for MDD have not revealed major disease loci [Bosker et al., 2011].
Neuroticism is a personality trait closely associated with MDD,
largely due to shared genetic risk factors [Hettema et al., 2006].
Although neuroticism provides a less complex phenotype (strongly
related to General Distress) [Clark et al., 1994], the three GWAS for
neuroticism yielded no signiﬁcant ﬁndings [Shifman et al., 2008;
van den Oord et al., 2008; Calboli et al., 2010].
In complex diseases, each gene has a small effect, but unfavorable
combinations of genes in a pathway may affect the output of the
pathway. This may affect downstream phenotypes. Thus, analyses
should be carried out at the pathway-level [Comings, 1998].
Whereas gene set analyses have been widely used in the ﬁeld of
microarrays, analyses of predeﬁned gene sets in genetic association
studies are very recent [Hooper-van Veen et al., 2006; Wang et al.,
2007; Holmans et al., 2009; Ruano et al., 2010]. Replication of
genetic associations with phenotypes was shown to be easier at
the pathway level than at the gene or SNP levels [Luo et al., 2010].
Different types of pathway analyses have been used [for review,
see Holmans, 2010]. The Global test is one example, based on a
regression model that includes all SNPs of the pathway. It tests
whether on average these are associated with the phenotype
[Goeman et al., 2004]. Interpretation is intuitive as the analysis
of a pathway is a direct extension of the analysis of single genes
or single SNPs. Further, the Global test performed consistently well
in the analysis of multiple SNPs in candidate genes [Chapman and
Whittaker, 2008; Pan, 2009] and candidate pathways [Deelen et al.,
2011].
In order to unravel the heterogeneity of symptoms among
patients with MDD, we aimed to identify pathways associated
with speciﬁc dimensions of depression and anxiety. Among
individuals with a lifetimeMDD,we used the Global test to identify




Data from 1,598 MDD cases from NESDA that passed quality
control in the GAIN-MDD study were used [Sullivan et al., 2009].
NESDA is a cohort study that follows patients with depressive
and/or anxiety disorders recruited between September 2004 and
February 2007 from mental health care organizations, primary
care, and community samples [Penninx et al., 2008]. Inclusion
criteria for genotyping were a lifetime diagnosis ofMDD according
to DSM-IV, assessed with the composite international diagnostic
interview (World Health Organisation version 2.1), age 18–
65 years, and self-reported western European ancestry. Individuals
not ﬂuent in Dutch or with a primary diagnosis of a psychotic
disorder, obsessive compulsive disorder, bipolar disorder, alcohol
or substance use disorder were excluded. For details see Boomsma
et al. [2008]. The Ethical Review Boards of all participating uni-
versities approved the research protocol. All subjects provided
written informed consent. For 200 of the 1,598 cases, no dimen-
sional phenotypedatawere available (questionnaires not returned).
These respondents were younger, more often men, and more often
with currentMDD. The remaining 1,398 individuals were the basis
of the present study.
MASQ-D30
The dimensions of the tripartite model were measured with the
30-item Dutch adaptation of the Mood and Anxiety Symptoms
Questionnaire (MASQ-D30) [Wardenaar et al., 2010]. TheMASQ-
D30 is a self-report questionnaire in which individuals rate how
much in the past week they have experienced ‘‘feelings, sensations,
problems, and experiences that people sometimes have’’ on a 5-
point Likert scale (1¼ not at all, 5¼ extremely). The MASQ-D30
consists of three 10-item subscales that measure General Distress,
Anhedonic Depression, and Anxious Arousal, and has good psy-
chometric characteristics [Wardenaar et al., 2010].TheMASQ-D30
was ﬁlled out by 1,398 cases of the GAIN MDD study. For 76
individuals, 1–4missing items (never more than 2 on a dimension)
were imputed with the mean score on the remaining items of the
dimension.
Genotype Data
Genotype data were collected as part of the GAIN-MDD study.
Genotyping was carried out by Perlegen Sciences according to strict
standard operating procedures. High-density oligonucleotide
arrays were used yielding 599,164 SNPs. Eight SNPs with duplicate
numbers were deleted and 73 mitochondrial SNPs were removed
for later analysis. From the remaining 599,083 SNPson the Perlegen
chip 435,291 passed quality control. For details see Boomsma et al.
[2008], Sullivan et al. [2009], Bosker et al. [2011].
Annotation
SNPswere assigned togenesusingRefSeq alignments to the genome
(UCSC, May 2010) and gene to RefSeq annotation (NCBI, build
35/hg17) [Wheeler et al., 2007]. We included SNPs between 5 kb
from50 end and2 kb from the 30 endof genes, as did others [Luciano
et al., 2011]. SNPs mapped to multiple genes were assigned to
each of these genes. The resulting gene map contained 18,601 well-
oriented Entrez Gene RefSeq clusters that deﬁned the gene boun-
daries, and covered 170,795 SNPs. With inclusion of 5 kb at 50
and 2 kb at 30 end, 188,017 SNPs were included. For men, SNPs on
the X-chromosome were encoded 0 or 2 [Clayton, 2008].
Gene Sets
Manually curated pathway databases like Biocarta andKegg [Ogata
et al., 1999] contain high-quality information, whereas the Gene
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Ontology (GO) database has extensive coverage by electronic
annotation [Ashburner et al., 2000]. Genes assigned the same
GO term have some aspect of their biology in common. In a
comparison of several pathway databases, results were comple-
mentary [Elbers et al., 2009]. The combined use was advised to
ensure both comprehensive coverage and use of the available
high quality information [Wang et al., 2010]. In the present study,
ﬁve groups of gene sets were analyzed: (1) 12 candidate pathways
manually curated from published data (see Supplementary
Online), (2) 117 GO cellular components, (3) 211 GO molecular
functions, (4) 609 GO biological processes, (5) 880 canonical
pathways from the Molecular Signatures Database v3.0
[Subramanian et al., 2007], which consists of 217 pathways from
BioCarta, 186 from KEGG [Ogata et al., 1999], and 430 from
Reactome [Croft et al., 2011].
Selection of GO Terms
GO terms were associated with genes using all evidence codes and
with the genes of its offspring. For this, the Entrez Gene to GO
association map org.Hs.egGO2ALLEGS from the R package
org.Hs.eg.db (v2.4.1) was used. This database contained 12,327
GO terms; to restrictmultiple testing, only those with 20–100 genes
were included. From this subset, only the roots of sub-trees were
selected to avoid overlap between gene sets. A similar approach
has been used byWang et al. [2007], who selected level 4 GO terms
among those with 20–200 genes.
Global Test
To test for associationof gene setswithGeneralDistress, Anhedonic
DepressionandAnxiousArousal, theRpackageGlobalTest (v5.1.5)
was used [Goeman et al., 2004]. The genotypes for all SNPs in a
pathway were included in a linear regression model, and the tested
null hypothesis was that no SNP in the pathway was associated
with the symptom dimensions. Because the Global test is based on
a multiple regression model, it automatically takes correlation
between SNPs, such as caused by linkage disequilibrium, into
account. Furthermore, because the Global test is constructed as a
test for a single parameter, regardless of the number of SNPs in the
pathway, the test is not biased towards large or small pathways
[Goeman et al., 2006]. For pathways associated with phenotypes
and for candidate pathways, additional Global tests were done for
the genes in the pathway to investigate which genes contributed to
the pathway-signal.
Control of False Discoveries
To control the risk of false-positive discoveries, Benjamini and
Hochberg false discovery rates (FDR-BH) were calculated for each
group of gene sets and for each of the outcomes. The use of FDR
is preferable to more traditional multiple testing controls because
they provide a better balance between the competing goals of
ﬁnding true positives versus controlling false discoveries, are
much less dependent on the number of tests conducted, and are
relatively robust against the effects of correlated tests [Benjamini
and Hochberg, 1995]. Five percent of the signiﬁcant ﬁndings were
allowed to be false discoveries.
Calculation of R2
An R2 measure of explained variance was calculated by ﬁtting a
linear ridge regression model to the MASQ-D30 phenotype using
the SNPs in the pathway as predictor covariates. The parameter of
the ridge penalty was determined by 10-fold cross-validation using
the penalized package (v0.9-32) in R [Goeman andOosting, 2011],
and the cross-validated results were used for the R2 calculation.
Because the R2 measure is obtained from a penalized model and
calculated using cross-validation, it can be interpreted as an
adjusted R2 measure.
Weighted Analysis
In our main analysis, all SNPs contribute equally to the pathway
score. As larger genes contain more SNPs, these get more weight
than small genes. Thus, this analysis favors pathways in which
multiple (independent) polymorphisms in large genes contribute
to the phenotype. If the phenotype is inﬂuenced by a few SNPs in
small genes, the effect is dilutedby themanynon-associatedSNPs in
the large genes. In this case, effects can more readily be detected by
ananalysis inwhich genes rather thanSNPshave equal contribution
to the pathway score. Therefore, all pathways were also analyzed
with the Global test using weights assigned to each of the SNPs.
The weight of a SNP was 1 divided by the number of SNPs in the
gene.
Analyses were carried out with R statistical software (v2.11.1).
RESULTS
Sample Description
Table I shows that 548 (39%) respondents had current MDD and
850 (61%) remitted MDD. For General Distress, the median score
was 21 (interquartile range (IQR) 15–29), for Anhedonic Depres-
sion 23 (IQR 16–31), for Anxious Arousal 15 (IQR 12–20). Thus,
there was considerable variability on the dimensions.
Gene Sets
Surprisingly, pathways around importantmolecules like serotonin,
noradrenalin, or BDNF were not associated with symptom dimen-
TABLE I. Characteristics of the Study Population (N¼ 1,398)
Characteristic
Age (years)a 43.0 (12.4)
Gender (n, % women) 965 (69%)
Onset age (years)a 27.4 (12.4)
Current MDD (past month) 548 (39)
Remitted MDD 850 (61)
MASQ-D30b
General distress 21 (15–29)
Anhedonic depression 23 (16–31)
Anxious arousal 15 (12–20)
aMean (SD).
bMedian (interquartile range, IQR).
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sions. Only Epigenetic Changes after Fear Conditioning was asso-
ciated with Anhedonic Depression.
After correction for multiple testing, no pathway remained
associated with General Distress (see Supplementary Online).
However, Anhedonic Depression was associated with six GO-
terms, and three gene sets were associated with Anxious Arousal.
The variance explained by these pathways ranged from 0.67% to
1.69%.
Figure 1 demonstrates that pathways associated with one of
the symptom dimensions show little signal for the other dimen-
sions. Thus, distinct gene sets contribute to different symptom
dimensions.
SNPs
The candidate pathwayEpigeneticChanges after FearConditioning
was associated with Anhedonic Depression (FDR 0.0267).
Figure 2A shows that the signal for this pathway was not driven
by a few important SNPs, as few SNPs showed small P-values.
Further, the signal was driven by SNPs in different genes (see
SupplementaryOnline for theotherpathways). Importantly, differ-
ent SNPs contributed to different dimensions.
Genes
For all signiﬁcant gene sets, several genes contributed to the path-
way signal. Even without adjustment for multiple testing few genes
had P-values <0.05 (see Supplementary Online). Figure 2B shows
associations of the genes in pathway Epigenetic Changes after Fear
Conditioning.
However, all GO terms associated with Anhedonic Depression
contained the gene NRG1 (unadjusted P-value 5.36 105), and
all GO-terms associated with Anxious Arousal contained FMN2
(unadjusted P-value 1.08 103). These genes contained 190 and
110 SNPs, respectively, and thus contributed importantly to the
pathway scores. The inﬂuence of these genes was much diminished
in the weighted analysis. Only the KEGG pathway Dorso-Ventral
Axis Formation and the GO-term Meiosis showed weak evidence
for association in the weighted analysis (both with adj. P¼ 0.0726)
(see Supplementary Online).
Weighted Analysis
In theweighted analysis, we again tested the 12 candidate pathways,
937 GO-terms and 880 canonical pathways for association with the
symptom dimensions. After adjustment for multiple testing, only
GO-term Endoplasmatic Reticulum Lumen was associated with
General Distress (see Table II).
DISCUSSION
We sought a genetic basis for the clinical heterogeneity among
patients withMDD.Our study revealed that distinct genetic factors
contribute to different dimensions of depression and anxiety. We
FIG. 1. Associations of the candidate pathways and signiﬁcant pathways with General Distress, Anhedonic Depression, and Anxious Arousal.
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identiﬁed seven pathways for Anhedonic Depression. If veriﬁed,
this implies that Anhedonic Depression is highly complex, and a
‘‘simple’’ treatment might be out of reach. However, in six of these
pathways the gene encoding neuregulin (NRG1) appeared. This
gene is an important candidate gene for schizophrenia [Mei and
Xiong, 2008]. If neuregulin proves to be a key feature of the
pathogenesis of Anhedonic Depression, it may provide an impor-
tant drug target. Three pathways were associated with Anxious
Arousal, and only one pathway was associated with General Dis-
tress, possibly due to the heterogeneity of this dimension [Den
Hollander-Gijsman et al., 2010]. Together, these results indicate
that the symptom dimensions underlying anxiety and depression
have different etiologies.
General distress has been identiﬁed as the core of internalizing
disorders [Hettema et al., 2006; Goldberg et al., 2009; Grifﬁth et al.,
2010]. Factor analysis of general distress items has clearly estab-
lished that the items cannot be reduced to a single dimension.
Separate subdimensions of depression, anxiety, and anger could be
distinguished. Although these factors were strongly correlated, this
indicates thatGeneralDistress is not unidimensional [Watson et al.,
2008]. The structure of General Distress needs to be unraveled to
identifymore homogeneous phenotypes of this important aspect of
emotional disorders.
The gene set associated with General Distress concerned mol-
ecules located in the endoplasmatic reticulum (ER). In the ER,
secretory and membrane proteins are synthesized and folded with
help from ER-chaperones. Malfolded proteins form aggregates
which are toxic and cause an ER stress response. A dysregulated
ER stress response was shown to be involved in neurodegenerative
and in mood disorders [Yoshida, 2007]. Furthermore, mood
stabilizers valproate and lithium increased expression of ER chap-
erones. In our study, unfavorable genotypes at these genes were
associated with General Distress.
Seven gene sets were associated with Anhedonic Depression.
Several of these had no clear function, but were collections of genes
with a common theme. They contained genes that were also
included in the candidate pathways, including BCL2, HDAC5,
ADRB2, andACVR1. Also, the themes were highly relevant: muscle
cell differentiation contained genes implicated in cell death, mes-
enchyme development ﬁts nicely with observations that mesen-
chymal stem cells increased hippocampal neurogenesis and
ameliorated depression in rodents [Tﬁlin et al., 2010], cardiac
cell differentiation contained motility-genes that are highly
expressed in the brain. However, it is unclear how these gene
FIG. 2. For the pathway Epigenetic Changes after Fear
Conditioning, the Global test result is decomposed, such that the
contribution is shown of each SNP (A), and each gene (B). The
results are sorted by P-value of Anhedonic Depression to
facilitate comparison of the three dimensions. A: The most left
SNP is rs17434924 in RELN, with P¼ 7.32 105 for Anhedonic
Depression, 9.99 104 for General Distress, and 6.83 102
for Anxious Arousal.
TABLE II. Gene Sets Associated With Symptom Dimensions
Description Nr SNPs P-value FDR-BH R2 (%)
General distress
1 Endoplasmatic reticulum lumen GO:0005788 470 4.10 104 0.0410 0.93
Anhedonic depression
1 Regulation muscle cell differentiation GO:0051147 634 3.99 105 0.0243 1.69
2 Regulation of protein binding GO:0043393 596 1.30 104 0.0260 0.86
3 Macromolecular complex disassembly GO:0032984 680 1.76 104 0.0260 0.84
4 Notch signalling pathway GO:0007219 1,041 1.78 104 0.0260 0.79
5 Cardiac cell differentiation GO:0035051 503 2.14 104 0.0260 0.67
6 Epigenetic changes after fear conditioning 367 1.27 103 0.0267 1.22
7 Mesenchyme development GO:0060485 690 3.38 104 0.0343 0.78
Anxious arousal
1 Dorso ventral axis formation Kegg hsa04320 478 1.85 105 0.0163 1.19
2 Meiosis I GO:0007127 371 3.60 105 0.0221 0.73
3 Cytokinesis GO:0000910 390 9.62 105 0.0293 0.74
VAN VEEN ET AL. 523
sets inﬂuence Anhedonic Depression. Below, we discuss GO terms
that represent biological processes.
Macromolecular complex disassembly (GO:0032984) contrib-
uted to Anhedonic Depression and consists of genes that regulate
the dynamic structure of the cytoskeleton. These genes regulate the
shape and functionof dendritic spines, structures critically involved
in learning and memory [Hotulainen and Hoogenraad, 2010].
Many of these genes have been associated with autism, mental
retardation, Alzheimer’s disease, and schizophrenia, which like
depression are neurodevelopmental or neurodegenerative condi-
tions. In rodents, both early and adult stresses lead to impaired
memory accompanied by morphological changes in the hippo-
campus and frontal cortex. There, cytoskeletal modiﬁcations were
associated with reduced density of dendritic spines and altered
structure of synaptic terminals [Yan et al., 2010]. Thus, a genetic
makeup associated with less synaptic structures necessary for
learning and memory may contribute to Anhedonic Depression.
Notch signaling (GO:0007219) also contributed to Anhedonic
Depression. The adult hippocampus generates new neurons, a
process in which Notch1 signaling is involved [Androutsellis-
Theotokis et al., 2006]. This neurogenesis has been associated
with sad mood [Doetsch and Hen, 2005] and was necessary for
behavioral effects of antidepressants [Santarelli et al., 2003; Guo
et al., 2009].
Candidate pathway Epigenetic Changes after Fear Conditioning
contributed to Anhedonic Depression. Epigenetic changes are
modiﬁcations of chromatin that have lasting inﬂuence on gene
expression. For instance, acetylation of histones by histone acetyl-
transferases reduces their afﬁnity for DNA and facilitates gene
expression. In contrast, deacetylation by histone deacetylases
(HDACs), or DNA methylation by DNA methyltransferases
(DNMTs) is associated with gene silencing. Classical fear condi-
tioning is based on Pavlov’s observations that neutral stimuli can
acquire affective properties due to associationwith aversive stimuli.
Animal models of fear conditioning have provided insight into
the biology of fear, much of which can be extended to human fear
and anxiety [Delgado et al., 2006]. Fear conditioning induced
hippocampal expression of DNMT3A and -3B, and DNMT
blockers inhibited fear conditioning [Miller and Sweatt, 2007].
Protein phosphatase-1 (PP1) suppresses memory formation and
was methylated (silenced) in fear conditioning [Miller and Sweatt,
2007].RELN encodes reelin, amemory-promoting gene,whichwas
demethylated (activated) in fear conditioning [Miller and Sweatt,
2007]. These epigenetic changes were also involved in depression.
In mice, anhedonia was accompanied by histone methylation in
hippocampus. Antidepressant imipramine reversed the anhedonia,
not by demethylation, but by increased acetylation of the histones
[Tsankova et al., 2006]. Thus, aversive environmental signals cause
epigenetic changes with lasting effects on mood and anxiety. The
genetic proﬁle for this pathwaymay render individualsmore or less
sensitive to adverse events. In our study, it was associated with
Anhedonic Depression.
Three pathways contributed to Anxious Arousal. The pathway
Dorso-Ventral Axis Formation represents a developmental path-
way, although the genes are also highly expressed in adult brain. The
pathway Cytokinesis regards the division of cytoplasm into two
daughter cells, but the generation of dendritic spines is a similar
process that shares involvement ofmany genes. Remarkablewas the
association of Anxious Arousal with GO-term Meiosis 1. This
pathway consists of genes encoding elements of the synaptonemal
complex (SC) and regulators of DNA recombination. The SC plays
a major role in chromosome pairing and genetic recombination
[Page and Hawley, 2003]. Intriguingly, components of the SC
[Dietrich and Been, 2001], and pairing of homologous chromo-
somes [Arnoldus et al., 1989] have been demonstrated in neurons
in brain tissue of rats. Moreover, DNA recombination and/or
DNA repair in the brain was necessary for long-term memory in
fear conditioning [Wang et al., 2003; Colon-Cesario et al., 2006;
Saavedra-Rodriguez et al., 2009]. Many proteins involved in
homologous recombination are also active in somatic DNA
recombination/repair. DNA recombination has been suggested
to contribute to neuronal diversity in the developing brain, like
V(D)J rearrangement contributes to antibody diversity in the
immune system [Chun and Schatz, 1999; Muotri and Gage,
2006]. Interestingly, in a GWAS for bipolar disorder, GO-term
V(D)J recombination was high-ranking [Holmans et al., 2009].
Thus, genetically determined variation in DNA recombination
in the brain may contribute to variation in Anxious Arousal.
However, the nature of this process remains to be elucidated.
Surprisingly, candidate pathways had little effect on the symp-
tom dimensions. Explorative network analyses may be more
likely to identify gene sets around seemingly important genes, as
they visualize interactions or shared functions of selected SNPs
[Baranzini et al., 2009; Vink et al., 2009]. Subsequent veriﬁcation
with Global test in a replication cohort would provide convincing
evidence for association.
In the pathways that showed signiﬁcant association, only few
genes and SNPs had small P-values. This is in line with the idea
that many SNPs with small effects are involved. Recent GWASs
in thousands of individuals have identiﬁed 50 SNPs associated
with height, which together explained 5% of phenotypic variance
[Yang et al., 2010]. Another 40% of variation was explained by the
rest of the SNPs. In this light, our observations of 0.67–1.69%
variance explained by the gene sets are promising.
In most pathway analyses, the pathway score is calculated from
gene scores. Often, the genes are summarized by the most signiﬁ-
cant SNP [Wang et al., 2007; Holmans et al., 2009; Yu et al., 2009].
As larger genes may contain more SNPs, these are more likely to
be selected [Wang et al., 2007]. To prevent this gene size bias, such
analyses need adjustment for gene size. However, adjustment for
gene size is not necessary but optional in the Global test. The
Global test uses all SNPs in a pathway, adjusts for correlation
between markers (i.e., linkage disequilibrium), and its results are
valid. Importantly, gene-based pathway tests have different proper-
ties than SNP-based pathway tests. In the SNP-based analysis,
NRG1 strongly inﬂuenced the pathway score for six GO-terms in
association with Anhedonic Depression. This gene contained 190
SNPs, and the signal was not due to a few highly signiﬁcant SNPs,
but rather to a larger number of less impressive signals. In the
weighted analysis, the contribution of these 190 SNPs was down-
weighted to let every gene have an equal contribution to the
pathway. This diminished the effect of NRG1 to a large extent.
SNP-based analyses may favor pathways in which multiple inde-
pendent signals are present in large genes. In gene-based analyses,
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single signals in smaller genes have as much weight as larger genes.
Therefore, it is not surprising that we observed different results in
the SNP-based and gene-based analyses. For only three pathways,
both the SNP-based and the gene-based results were in the top-10
associations.
Two other (regression) methods also favor pathways containing
genes with multiple, independent disease-associated SNPs. GRASS
jointly analyses principal components within genes to compute a
pathway score [Chen et al., 2010], and the Plink pathway score is
the average statistic of all the (selected) SNPs in the pathway
[Purcell et al., 2007]. In the brain, many very large genes are
expressed, so for psychiatric disorders, the power of the Global
test, GRASS and Plink set-test to incorporate multiple indepen-
dent effects in these genes may be favorable over other pathway
approaches. These methods were shown to yield similar results
[Deelen et al., 2011].
Symptoms of depression and anxiety are often used to measure
state effects, like response to treatment. However, as these symp-
toms were shown to be quite stable during a 7- to 8-year follow-up
period, they also possess trait-like characteristics [Ormel and
Wohlfarth, 1991; Kendler and Gardner, 2011]. The stable part of
symptoms was demonstrated to reﬂect the level of neuroticism,
which is predetermined by genes and childhood adversities. The
variable part of symptoms of depression and anxiety was shown to
be due to episodes of MDD and GAD, caused by genetic risk and
adversities during childhood and recent adulthood [Kendler and
Gardner, 2011]. In line with this, among patients with a diagnosis
of depression and/or anxiety at baseline, 2-year course trajectories
were predicted by baseline scores for dimensions of depression and
anxiety [Wardenaar et al., 2012]. Thus, symptoms of depression
and anxiety seem tohave a strong genetic basis. Indeed, twin studies
have demonstrated large effects of genetic factors on symptoms of
depression and anxiety [Gillespie et al., 2004; Boomsma et al., 2005;
Kendler et al., 2008]. Likewise, a substantial genetic component has
beendemonstrated forGeneralDistress andAnhedonicDepression
[Clark and Watson, 2008].
Previously, our group has shown distinct associations of General
Distress, Anhedonic Depression, and Anxious Arousal with differ-
ent aspects of the hypothalamo-pituitary-adrenal (HPA) axis
among subjects with a lifetime diagnosis of MDD [Wardenaar
et al., 2011]. Our present observations that these dimensions are
associated with distinct gene sets provide further validation of
the dimensions of the tripartite model as promising clinical phe-
notypes for etiologic research.
A major goal for future DSM is to incorporate the dimensional
natureofpsychopathology into thediagnostic system.Comorbidity
can then be recognized as a logical consequence of shared risk
[Andrews et al., 2009]. Anhedonic Depression is not unique to
depressive disorders, but also associated with social phobia and
agoraphobia, bipolar disorder, and schizophrenia [Mineka et al.,
1998; Bienvenu et al., 2007; Horan et al., 2008]. Thus, the gene sets
we identiﬁed to be associated with Anhedonic Depression in
patients with MDD may be relevant for those disorders as well.
As these dimensions of depression and anxiety have distinct
etiology, it is likely that they are also separate targets of cognitive or
pharmacological treatment [Tang et al., 2009]. In time, the rapidly
growing literature on the neurobiological and genetic correlates of
these dimensions may help identify targets for pharmacological
intervention [Whittle et al., 2006].
Unfortunately, we did not have a replication cohort, so veriﬁ-
cation of our ﬁndings awaits subsequent research. Further, our
sample consisted of patients only. Compared to healthy controls,
patients will on average have higher symptom scores and a higher
number of unfavorable variants in contributing gene sets. The lack
of healthy controls in our analyses reduces power to identify genetic
risk factors, as the positive side of the continuum is not represented:
healthy controls will on average have fewer symptoms and a higher
number of favorable variants in the contributing gene sets. There-
fore, the range of scores was reduced, and thereby the power to
detect genetic effects. However, the interpretation of gene sets
associated with symptom dimensions need not be very different
whether controls are included or not. As this case-only analysis
covered a broad range of psychiatric outpatients, we were able to
test our dimensional approach as a means to account for hetero-
geneity across real-world patients. Strengths of this study were the
well-characterized patients, formal hypothesis testing of predeﬁned
pathways, and relatively homogeneous phenotypes.
To conclude, we identiﬁed pathways associated with Anhedonic
Depression and Anxious Arousal. Many of these processes were
known from animal studies to be involved in depression or anxiety,
and now we demonstrated that common variability in these proc-
esses contributes to psychopathology in humans. Our observations
help to understand the heterogeneity of symptoms among patients
with depression. These pathways provide leads for further study to
understand the neurobiology of depression and anxiety.
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